HomeInsightsStock Comparison

Cipla Ltd vs Sun Pharmaceuticals Industries Ltd Stock Comparison

Cipla Ltd vs Sun Pharmaceuticals Industries Ltd Stock Comparison

Last Updated on: Apr 27, 2025

Key Highlights

  • The Latest Trading Price of Cipla Ltd is ₹ 1525 as of 25 Apr 15:30.
  • The P/E Ratio of Cipla Ltd changed from 22 on March 2020 to 29.3 on March 2024 . This represents a CAGR of 5.90% over 5 yearsThe P/E Ratio of Sun Pharmaceuticals Industries Ltd changed from 22.5 on March 2020 to 40.6 on March 2024 . This represents a CAGR of 12.53% over 5 years.
  • The Market Cap of Cipla Ltd changed from ₹ 34103 crore on March 2020 to ₹ 120673 crore on March 2024 . This represents a CAGR of 28.75% over 5 yearsThe Market Cap of Sun Pharmaceuticals Industries Ltd changed from ₹ 84504 crore on March 2020 to ₹ 388812 crore on March 2024 . This represents a CAGR of 35.70% over 5 years.
  • The revenue of Cipla Ltd for the Dec '24 is ₹ 7294 crore as compare to the Sep '24 revenue of ₹ 7241 crore. This represent the growth of 0.73% The revenue of Sun Pharmaceuticals Industries Ltd for the Dec '24 is ₹ 14141 crore as compare to the Sep '24 revenue of ₹ 13645 crore. This represent the growth of 3.63%.
  • The ebitda of Cipla Ltd for the Dec '24 is ₹ 2210 crore as compare to the Sep '24 ebitda of ₹ 2076 crore. This represent the growth of 6.47% The ebitda of Sun Pharmaceuticals Industries Ltd for the Dec '24 is ₹ 4158 crore as compare to the Sep '24 ebitda of ₹ 4292 crore. This represent the decline of -3.13%.
  • The net profit of Cipla Ltd changed from ₹ 996.58 crore to ₹ 1583 crore over 7 quarters. This represents a CAGR of 30.30% The net profit of Sun Pharmaceuticals Industries Ltd changed from ₹ 2013 crore to ₹ 2917 crore over 7 quarters. This represents a CAGR of 23.62% .
  • The Dividend Payout of Cipla Ltd changed from 14.24 % on March 2020 to 25.74 % on March 2024 . This represents a CAGR of 12.57% over 5 yearsThe Dividend Payout of Sun Pharmaceuticals Industries Ltd changed from 29.89 % on March 2020 to 113.33 % on March 2024 . This represents a CAGR of 30.55% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Cipla Ltd

  • Cipla Ltd is one of the leading pharmaceutical companies in India.
  • The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
  • Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
  • With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
  • Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Ltd was incorporated in the year 1935 with the name Chemical, Industrial & Pharmaceutical Laboratories Ltd.

About Sun Pharmaceuticals Industries Ltd

  • Sun Pharmaceutical Industries Limited including its subsidiaries and associates is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.
  • The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies.
  • It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates.
  • The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids.

Cipla Ltd News Hub

News

Cipla's Goa API facility receives VAI status from USFDA

According to an exchange filing dated 20 January 2025, the USFDA conducted an inspection o...

Read more

21 Apr 2025 11:32

News

Cipla allots 23,282 equity shares under ESOS

Cipla has allotted 23,282 fully paid-up equity shares of Rs 2 each, pursuant to exercise o...

Read more

17 Apr 2025 16:12

News

Cipla receives USFDA approval for Protein-bound Paclitaxel for Injectable Suspension

Cipla has received final approval from the United States Food and Drug Administration (USF...

Read more

11 Apr 2025 09:27

News

Cipla jumps on receiving approval from USFDA for protein-bound Paclitaxel

Cipla's formulation is an AB-rated therapeutic equivalent of Abraxane and is indicated for...

Read more

11 Apr 2025 10:12

News

Cipla to table results

Cipla will hold a meeting of the Board of Directors of the Company on 13 May 2025. Powered...

Read more

08 Apr 2025 09:40

News

USFDA classifies cGMP inspection of Cipla's Virgonagar facility as VAI

Cipla has classified its current Good Manufacturing Practices (cGMP) inspection of the com...

Read more

08 Feb 2025 11:16

Sun Pharmaceuticals Industries Ltd News Hub

News

Sun Pharma and Israel-based Moebius Medical publish two articles on MM-II

Sun Pharmaceutical Industries and Israel-based Moebius Medical announced today the publica...

Read more

24 Apr 2025 09:12

News

Sun Pharmaceutical launches Fexuprazan tablets 40 mg in India

Sun Pharmaceutical Industries has launched Fexuprazan tablets 40 mg in India under the bra...

Read more

07 Apr 2025 09:07

News

Sun Pharma launches Fexuprazan tablets 40 mg in India

The drug, available in 40 mg tablets, is approved as a new treatment for adults with erosi...

Read more

07 Apr 2025 10:23

News

Sun Pharma completes acquisition of Antibe Therapeutics Inc., Canada

Sun Pharmaceutical Industries has completed 100% acquisition of Antibe Therapeutics Inc., ...

Read more

18 Mar 2025 15:01

News

Sun Pharma gains as arm acquires Antibe Therapeutics for $4.5 Million

Sun Pharmaceuticals Industries is a leading global pharmaceutical company with a specialty...

Read more

18 Mar 2025 12:53

News

Sun Pharmaceuticals Industries Ltd soars 0.96%, gains for fifth straight session

Sun Pharmaceuticals Industries Ltd rose for a fifth straight session today. The stock is q...

Read more

17 Mar 2025 13:00

SWOT Analysis Of Cipla Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Sun Pharmaceuticals Industries Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Cipla Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Sun Pharmaceuticals Industries Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Cipla Ltd and Sun Pharmaceuticals Industries Ltd

Which company has a larger market capitalization, Cipla Ltd or Sun Pharmaceuticals Industries Ltd?

Market cap of Cipla Ltd is 123,201 Cr while Market cap of Sun Pharmaceuticals Industries Ltd is 428,725 Cr

What are the key factors driving the stock performance of Cipla Ltd and Sun Pharmaceuticals Industries Ltd?

The stock performance of Cipla Ltd and Sun Pharmaceuticals Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Sun Pharmaceuticals Industries Ltd?

As of April 27, 2025, the Cipla Ltd stock price is INR ₹1525.5. On the other hand, Sun Pharmaceuticals Industries Ltd stock price is INR ₹1786.85.

How do dividend payouts of Cipla Ltd and Sun Pharmaceuticals Industries Ltd compare?

To compare the dividend payouts of Cipla Ltd and Sun Pharmaceuticals Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions